UNSPSC 51182065: Prasterone sulfate

This classification denotes a therapeutic androgen C19H28O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57B09Q7FJR, chemically known as androst-5-en-17-one, 3-(sulfooxy)-, (3.beta.)-, but more generally known as prasterone sulfate, which bears US NIH Compound Identifier 12594. European Medicines Agency schedules Prasterone sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34548. Most nations, for tariff and trade purposes, schedule prasterone sulfate under HS 29372900 and SITC 54153.

As of Q4 2014, PRASTERONE SULFATE remains US FDA's Preferred Term for this commodity. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC=C4[C@@]3(CC[C@@H](C4)OS(=O)(=O)O)C.

UNSPSC 51182065 Prasterone sulfate is a Commodity code capturing pharmaceutical products that state and local health agencies and cooperative purchasing alliances procure through multi-source generic and OTC product frameworks. The scope of work under this code spans manufacturer supply agreements for specific pharmaceutical products identified by National Drug Code (NDC), with vendors required to provide detailed product specifications including SKUs, UPCs, generic descriptions, strength, dosage form, and packaging configurations. State and local buyers use these contracts to secure ongoing access to generic pharmaceuticals and OTC products across distributed facility networks, typically through authorized pharmaceutical wholesalers rather than direct institutional purchase.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuer, with participation spanning multiple states including Oregon. MMCAP issued an RFP for Generic Multi Source Pharmaceuticals and Over the Counter Products (Solicitation S1070000015802) on January 20, 2026, with proposals due March 26, 2026. The solicitation requires vendors to establish relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP and DSCSA compliance, carry specified insurance coverage including $5 million commercial general liability and $2 million network security liability, and offer pricing flexibility through flat-price, net-price, or WAC-minus structures. Contract awards are effective July 1, 2026, with a two-year initial term and optional extensions; all products must be available in the marketplace by May 15, 2026, and carry at least one-year expiration dates with minimum six-month shelf life. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing stability, and 15 percent combined on administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee.